The former NASDAQ biotech stock trading under the ticker CRTX is not a buy right now because the original US company Cortexyme no longer exists on the US market. Cortexyme officially rebranded to Quince Therapeutics and moved its stock ticker to QNCX. Today, Quince Therapeutics has stopped all drug development and is looking to sell itself or merge with another business.
If you see a stock actively trading under the ticker symbol CRTX, you are likely looking at CRISM Therapeutics, a tiny, high-risk company listed on the London Stock Exchange (LSE). Neither option offers a safe opportunity for investors right now. What Happened to the Original CRTX Stock?
The original biotech firm, Cortexyme, was famous for trying to make an Alzheimer’s drug. In late 2021, that drug failed its main clinical trial. The stock lost most of its value. To try and survive, the company changed its direction:
The Name Change: In August 2022, Cortexyme became Quince Therapeutics.
The New Ticker: The US stock symbol changed from CRTX to QNCX.
The New Focus: The company stopped working on Alzheimer’s and focused on rare diseases. The Current State of Quince Therapeutics (QNCX)
The pivot did not save the company. Quince Therapeutics has faced heavy financial trouble.
No Revenue: The company did not make any revenue in 2023, 2024, or 2025.
No More Drugs: Quince has completely shut down all drug development.
Liquidation Mode: The company is now just trying to save its remaining cash. They are actively looking for a merger or a total sale of the business.
The stock has crashed heavily, losing over 96% of its value since the start of the year. It now trades as a “penny stock” at around \(1.01. Quince Therapeutics Inc (QNCX) -6.82% today Closed: 23:00 • <a href="https://www.google.com/intl/en_us/googlefinance/disclaimer">Disclaimer</a> After hours: 02:45 Jun 6, 2026 Mkt cap\)16.46M USD 52-wk high45.50 P/E ratio- 52-wk low0.80 Div yield- The UK Stock: CRISM Therapeutics (CRTX)
If you search for “CRTX” on international exchanges, you will find CRISM Therapeutics Corporation on the London Stock Exchange. This is a completely separate UK-based medical business, but it is also highly speculative.
Micro-Cap Status: CRISM is a tiny “micro-cap” stock with a market value of less than \(10 million.</p> <p><strong>Weak Financials:</strong> Its yearly revenue is under \)33,000, and it operates at a net loss.
Dilution Risk: The company increased its total share count by 58% in the past year to raise money, which lowers the value of existing shares. Final Verdict: Avoid Both Stocks
You should stay away from both stocks right now. CRTX (Cortexyme) is a ghost of a failed biotech firm that has abandoned its business model. QNCX (Quince) is a failing shell company trying to find a buyer. CRTX on the LSE is an incredibly small, volatile company with almost no revenue.
Biotech investing is always risky, but buying into companies with dead pipelines or no revenue is purely gambling. Look for healthy biotech firms with strong pipelines and plenty of cash instead.
To help you find better investment options, would you like to explore other biotech stocks with active clinical trials, or do you want to learn how to check a biotech company’s cash runway?
AI responses may include mistakes. For financial advice, consult a professional. Learn more Cortexyme (CRTX) | Finance information – Stockcircle
Leave a Reply